John B. Cannon, Ph.D Prospects-for-Pharmaceutical-Treatment-of-AchondroplasiaDownload Achondroplasia is a form of …
QED
BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia Data Accepted to ENDO 2020
SAN FRANCISCO, May 11, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics …
QED COVID-19 Update
Dear Chandler Project, We at QED know that this is a challenging time for all families. We hope that you are all …
Study of Infigratinib in Children With Achondroplasia
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, …
QED Achondroplasia Clinical Update
QED Therapeutics, Inc. (“QED”), a subsidiary of BridgeBio Pharma, Inc. (“BridgeBio”) focuses on bringing medicine to …